icon-    folder.gif   Conference Reports for NATAP  
 
  19th International Workshop on
Co-morbidities and Adverse
Drug Reactions in HIV
Back grey_arrow_rt.gif
 
 
 
RETROSPECTIVE OBSERVATIONAL STUDY TO DEFINE THE PREVALENCE OF SARCOPENIA IN HIV-INFECTED PATIENTS
 
 
  Reported by Jules Levin
19th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV, Milan, Italy Oct 23-25 2017
 
from Jules: I suspect that sarcopenia, low muscle mass - which appears to be worse in HIV+ and worse in HIV+ wome tun men as found in this study, and it progresses over time in HIV+ women as found in this study - I suspect that sarcopenia is a major contributor to falls, bone loss and most importantly to frailty & falls & fractures. Exercise to strengthen muscles throughout the entire body particularly the entire legs is I think very important to prevent sarcopenia.
 
Echeverria P; Bonjoch A, Puig J, Estany C, Ornella A, Clotet B, Negredo E. Lluita contra la Sida Foundation Hospital Universitari Germans Trias i Pujol Badalona, Spain

1109171

1109172

1109173

1109174

1109175

(a) The final model of multivariate analyses was adjusted for the following predictors: Age, gender, time of diagnosis of HIV-infection >5 years,
BMI <20 and total cholesterol <140 mg/dL.
•The univariate analysis showed that sarcopenia was more prevalent in women than in men [RR 4.502 (95% CI: 3.227-6.281), p=0.001], in patients with osteopenia [RR 0.415 (95% CI: 0.303-0.568), p<0.001], and in patients with osteoporosis [RR 0.237 (95% CI: 0.151-0.374), p<0.001]